Literature DB >> 18417061

Will CETP inhibition survive the demise of torcetrapib?

Anders G Olsson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18417061     DOI： 10.1007/s11883-008-0014-2

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  11 in total

1.  Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.

Authors:  John J P Kastelein; Sander I van Leuven; Gregory W Evans; Ward A Riley; James H Revkin; Charles L Shear; Michiel L Bots
Journal:  Curr Med Res Opin       Date:  2007-04       Impact factor: 2.580

2.  Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.

Authors:  Greetje J de Grooth; Jan Albert Kuivenhoven; Anton F H Stalenhoef; Jacqueline de Graaf; Aeilko H Zwinderman; Jan L Posma; Arie van Tol; John J P Kastelein
Journal:  Circulation       Date:  2002-05-07       Impact factor: 29.690

Review 3.  Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.

Authors:  Philip J Barter; John J P Kastelein
Journal:  J Am Coll Cardiol       Date:  2006-01-18       Impact factor: 24.094

4.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

5.  Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

Authors:  John J P Kastelein; Sander I van Leuven; Leslie Burgess; Greg W Evans; Jan A Kuivenhoven; Philip J Barter; James H Revkin; Diederick E Grobbee; Ward A Riley; Charles L Shear; William T Duggan; Michiel L Bots
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

Review 6.  The role of CETP inhibition in dyslipidemia.

Authors:  Karim El Harchaoui; Wim A van der Steeg; Erik S G Stroes; John J P Kastelein
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

7.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

8.  Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.

Authors:  Rajesh Krishna; Matt S Anderson; Arthur J Bergman; Bo Jin; Marissa Fallon; Josee Cote; Kim Rosko; Cynthia Chavez-Eng; Ryan Lutz; Daniel M Bloomfield; Maria Gutierrez; James Doherty; Fredrick Bieberdorf; Jeffrey Chodakewitz; Keith M Gottesdiener; John A Wagner
Journal:  Lancet       Date:  2007-12-08       Impact factor: 79.321

9.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

Authors:  Steven E Nissen; Taro Tsunoda; E Murat Tuzcu; Paul Schoenhagen; Christopher J Cooper; Muhammad Yasin; Gregory M Eaton; Michael A Lauer; W Scott Sheldon; Cindy L Grines; Stephen Halpern; Tim Crowe; James C Blankenship; Richard Kerensky
Journal:  JAMA       Date:  2003-11-05       Impact factor: 56.272

10.  Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Authors:  Michiel L Bots; Frank L Visseren; Gregory W Evans; Ward A Riley; James H Revkin; Charles H Tegeler; Charles L Shear; William T Duggan; Ralph M Vicari; Diederick E Grobbee; John J Kastelein
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.